The page you are looking for doesn't exist or another error occurred.
Please use the menu above or the search form below to try another section.
This month, we welcomed a total of 43 aspiring young scientists from across London to the Barts Cancer Institute (BCI), Queen Mary University of London, where they had the opportunity to meet researchers, try their hands in the lab and learn more about what it takes to become a scientist.
Molecules exhaled in the breath may provide clues to detect blood cancer, according to new research by scientists at Barts Cancer Institute. The findings could enable the development of a blood cancer breathalyser, providing a rapid, low-cost way to detect disease.
Researchers have discovered a new mechanism by which B cells – antibody-producing immune cells – use a cellular recycling process called autophagy to control changes to their DNA essential for antibody improvement. The findings could have future implications for the development of certain blood cancers and autoimmune diseases.
Scientists have uncovered how bowel cancer cells imitate our gut’s natural healing processes to adapt, spread and grow. The findings researchers at Barts Cancer Institute could lead to new treatment strategies aimed at preventing cancer spread.
A new strategy to help powerful cancer-targeting immune cells, known as CAR-T cells, infiltrate pancreatic tumours has been developed by researchers at Barts Cancer Institute, Queen Mary University of London. The unique three-pronged approach could pave the way for making CAR-T cell therapy—a treatment that has transformed care for certain blood cancers—effective against pancreatic cancer, a disease that remains very difficult to treat.
Women of African or South Asian genetic ancestry tend to develop breast cancer and die at a younger age than women of European ancestry, according to new research by Barts Cancer Institute, Queen Mary University of London. The study, which looked at clinical and genetic data from over 7,000 women with breast cancer, also found important genetic differences in these women’s cancers that could impact their diagnosis and treatment.